Immune response analysis using cancer patients' cells during chemotherapy
2014
Attikon University Hospital, Athens, Greece
Recently, immune evasion by malignant cells has been identified as one of the crucial hallmarks of cancer development. Regulatory T-cells (Tregs) are the most extensively studied suppressive cells and increasing evidence suggests that cancer progression correlates with an increase in Treg activity. In the present study, the researchers aimed at investigating the effect of chemotherapy on the number and functionality of peripheral regulatory and effector T-cells in cancer patients. Regulatory and effector T-cells were purified from cancer patients and cultured in vitro to assess proliferative capacity before and during various chemotherapeutic regimens. The obtained results showed a clear shift in favour of regulatory T-cells during chemotherapy. There was a relative increase of regulatory to effector T-cells and suppressive activity was augmented. Differences were noted comparing different chemotherapy approaches, underlining the importance to better understand the effect of chemotherapeutics on the immune response to select the most advantageous drug, particularly if the drug is to be used in combination with immunotherapeutics.
The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
Anna Koumarianou
Added on: 09-14-2021
[1] https://ehoonline.biomedcentral.com/articles/10.1186/2162-3619-3-3[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
